肿瘤细胞治疗研究
ALL SOURCES
Monospecific and Bispecific Chimeric Antigen Receptor (CAR) T-cell Therapy in Multiple Myeloma: A Systematic Review, Meta-analysis and Meta-regression
分析了 44 个队列（2 个一线队列和 42 个复发/难治性队列）的 52 篇报告，共纳入 1833 例患者。
Slowing Mortality Improvements in Multiple Myeloma Despite Novel Therapies: Global Disparities by Sociodemographic Index, 1990-2023.
方法 发病率和死亡率数据提取自Global Burden of Disease 2023 Results Tool，包括95%不确定性区间。
Comprehensive review on outcomes from Phase 3 clinical trials of drugs in multiple myeloma.
本综述整合了近期3期试验的证据，为临床医生提供了MM个性化、风险适应管理的更新框架。
Comparative efficacy and safety of BCMA-targeted CAR T cells and BiTEs in relapsed/refractory multiple myeloma: a meta-analysis of interventional and
共纳入 26 项研究，包含 2,246 例患者。
The Evolving Treatment Landscape for the Elderly Multiple Myeloma Patient: From Quad Regimens to T-Cell Engagers and CAR-T.
多发性骨髓瘤（MM）主要是一种老年疾病。
CAR-T-Cell Therapy in Multiple Myeloma: B-Cell Maturation Antigen (BCMA) and Beyond.
多发性骨髓瘤 (MM) 的治疗干预领域已取得重大进展，导致其临床管理发生变革性转变。
Extramedullary relapse of multiple myeloma presenting as space-occupying lesion in liver treated with daratumumab, pomalidomide, dexamethasone and ben
多发性骨髓瘤（MM）患者的髓外复发通常与生化反应丧失和骨髓中出现可测量残留病灶相关。
Real-world outcomes in relapsed refractory multiple myeloma patients exposed to three or more prior treatments: an analysis from the ANZ myeloma and r
这项回顾性分析证实，澳大利亚RRMM患者的结局一致较差。仍然迫切需要提高CAR-T等新型治疗在临床试验之外的可及性。
共 8 条
MEMBER ACCOUNT
登录成功会直接打开下一页。
